BACKGROUND: The beneficial effects of parasympathetic stimulation have been reported in left heart failure, but whether it would be beneficial for pulmonary arterial hypertension (PAH) remains to be explored. Here, we investigated the relationship between parasympathetic activity and right ventricular (RV) function in patients with PAH, and the potential therapeutic effects of pyridostigmine (PYR), an oral drug stimulating the parasympathetic activity through acetylcholinesterase inhibition, in experimental pulmonary hypertension (PH).
P
ulmonary arterial hypertension (PAH) is characterized by progressive pulmonary vascular remodeling and increased right ventricular (RV) afterload, which eventually leads to right heart failure. 1 Despite the significant progress in the treatment of PAH, its prognosis remains grim. 2, 3 Cardiovascular autonomic dysfunction, or more specifically, increased sympathetic nervous system activity, 4 ,5 parasympathetic nervous system withdrawal, 6 and blunted baroreflex sensitivity 7, 8 are associated with disease progression and poor prognosis in PAH. It has, however, never been directly related to RV function. 7, 9 We and others have demonstrated that targeting the sympathetic nervous system could be a promising therapy to improve RV function and pulmonary vascular remodeling. [10] [11] [12] Hypothetically, autonomic function can also be restored via parasympathetic stimulation. However, this has not been investigated yet in the context of PAH.
Local cardiac parasympathetic activity is mediated via 2 types of receptors, the nicotinic receptors (at the preganglionic level) and the muscarinic receptors (postganglionic level). Nicotinic receptors are activated by acetylcholine released from parasympathetic nerve terminals at the preganglionic level, and subsequently the muscarinic receptors are activated at the organ level. 13 Increased expression of the nicotinic receptor was observed in the left ventricle in a pressure-overload rat model. 14 This finding suggests a compensatory cholinergic response to reduced parasympathetic activity. Another study in experimental left heart failure provided evidence that pyridostigmine (PYR), an oral drug that stimulates the parasympathetic nervous system through acetylcholinesterase inhibition, was able to improve autonomic and left ventricular function. 15, 16 Furthermore, donepezil, a different acetylcholinesterase inhibitor that crosses the blood-brain barrier, was also shown to improve cardiac function in left heart failure 17 and attenuated the development of hypertension in spontaneously hypertensive rats. 18 In the present study, we chose to use PYR, a long approved drug for myasthenia gravis, with a more favorable pharmacological profile than donepezil, to activate the parasympathetic nervous system.
Here, we aim to investigate the relationship between parasympathetic activity and RV function in patients with idiopathic/hereditary PAH. In addition, we aim to determine the potential therapeutic effects of parasympathetic activity stimulation by PYR in an experimental pulmonary hypertension (PH) rat model.
METHODS
The data, analytic methods, and study materials for the purposes of reproducing the results or replicating procedures can be made on request to the corresponding author who manages the information. Because cardiac MRI , right heart catheterization, and cardiopulmonary exercise test data were obtained for clinical purposes and analyzed retrospectively, the Medical Ethics Review Committee of the VU University Medical Center did not consider this study to fall within the scope of the Medical Research Involving Human Subjects Act. Therefore, no additional approval was acquired.
Parasympathetic Nervous System Activity and RV Function in Patients With PAH
We retrospectively reviewed 112 patients with idiopathic and hereditary PAH seen at the VU University Medical Center (Amsterdam, the Netherlands) between 2002 and 2015, who underwent a maximal cardiopulmonary exercise test and cardiac MRI for clinical reasons. Eight healthy volunteers who underwent a maximal cardiopulmonary exercise test were used as a control group. Heart rate recovery was used as a surrogate of parasympathetic activity. 19 Heart rate recovery was defined as the difference in heart rate at the maximum workload and at 30 seconds, 60 seconds, and 120 seconds after completion of the cardiopulmonary exercise test. RV ejection fraction (RVEF) was used as a parameter of RV function, and the cutoff value of 41% was selected based on the median.
Human RV and Lung Samples
Explanted RV tissue samples were collected from patients with PAH undergoing heart/lung transplantation (n=11) and compared with RV tissue obtained from nonfailing controls (control; n=9). 20 Human cardiac tissue collection was approved by the Human Research Ethics Committee of The University of Sydney (AU/1/961515) and the Université Paris-Sud-Inserm U999 (ID RBC 2008-A00485-50). Control lung tissues and pulmonary arteries were obtained from patients undergoing surgery for lung carcinoma (control; n=4). Samples were obtained distant from the malignant lesion and were dissected by a pathologist. Lung tissues and pulmonary arteries were also obtained from patients with PAH undergoing lung
Clinical Perspective
What Is New?
• This translational study demonstrates that reduced right ventricle function in patients with pulmonary arterial hypertension is associated with reduced systemic and local parasympathetic activity • Chronic pharmacological parasympathetic stimulation by pyridostigmine, an acetylcholinesterase inhibitor, improved survival and right ventricle function and reduced pulmonary vascular remodeling in experimental pulmonary hypertension.
What Are the Clinical Implications?
• The parasympathetic system may be a novel potential therapeutic target in pulmonary arterial hypertension.
Cholinergic System in Human Samples
Acetylcholinesterase (AchE) activity (see Methods in the online-only Data Supplement) and protein expression of cholinergic receptors were evaluated in RV, pulmonary artery, and lung homogenates from PAH and control patients by Western blot analyses. In the current study, we evaluated the expression of the following cholinergic receptors: the α-7 nicotinic acetylcholine receptor (α-7nAchR; 1:1000; AB24644; Abcam), a receptor that can activate the anti-inflammatory cholinergic pathway, 21 and muscarinic acetylcholine type 2 receptor (m2AchR; 1:1000; MA3-044; Thermo Scientific), a receptor related to negative inotropic effects via inhibition of adenylate cyclase. 22 Moreover, α-7nAchR was evaluated by immunofluorescence in lung sections from patients with PAH and controls.
Cell Proliferation Assay of Patients With PAH
Pulmonary microvascular endothelial cells (MVECs) were isolated from patients that underwent lobectomy. The study was approved by the Institutional Review Board of the VU University Medical Center (Amsterdam, the Netherlands). Endothelial cell isolation and cultures of the smallest pulmonary vessels were performed as previously described. 23 Cell proliferation was assessed by the 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide (Sigma-Aldrich) assay as described previously. 24 Cells were seeded in a 96-well plate at a density of 3 × 10 3 cells/well and incubated overnight. Cells were made quiescent by incubation in medium without fetal calf serum for 2 hours. Cells were then treated with vehicle or various concentrations of PYR for 2 hours followed by fetal calf serum (10% v/v) stimulation for 24 hours. After the incubation, cells were incubated with 10 µL of 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide reagent (5 mg/mL) for 2.5 hours at 37°C. The 3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide reagent was removed and 100 μL of isopropanol was added to each well. The plate was wrapped in an aluminum foil and incubated for 15 minutes on a shaker. Colorimetric analysis was performed with an enzyme-linked immunosorbent assay plate reader. This experiment (in quadruplicate) was repeated at least 3 times.
Human 3D-Engineered Heart Tissue
For regulatory reasons, we were not permitted to include a PYR-control group in the main experimental study. Therefore, we included a study on the effects of PYR on 3D-engineered heart tissue (EHT), generated from iCell cardiomyocytes 2 (Cellular Dynamics International), which are human induced pluripotent stem cell-derived cardiomyocytes, mixed with Matrigel (Corning, 354234), bovine fibrinogen (Sigma, F8630), plus aprotinin (Sigma, A1153) and thrombin (Sigma, T7513) (for details see the onlineonly Data Supplement). 25 
Experimental PH
All animal experiments were approved by the Institutional Animal Care and Use Committee of the VU University, Amsterdam, the Netherlands (FYS 14-17).
Sugen/Hypoxia Rat Model of PH
Male Sprague Dawley rats were used (n=31, 125-150 g; Charles River). One week before PH induction, a pressure telemetry device (TA11PA-C40, Data Science International) was implanted in the abdominal aorta in a subgroup of rats (n=4-6) for heart rate and blood pressure variability analysis. 26 PH was induced by a single subcutaneous injection of a vascular endothelial growth factor inhibitor (SU5416, 25 mg/kg body mass; Tocris Bioscience) dissolved in 0.5% carboxymethylcellulose, followed by 4 weeks of hypoxia exposure (10% oxygen; Biospherix Ltd) maintained by a nitrogen generator (Avilo) and reexposed to normoxia for maximally 10 weeks. The control group (controls; n=7) received a carboxymethylcellulose injection and was housed in normoxic conditions until the end of study ( Figure I in the online-only Data Supplement).
27

PYR Treatment and Hemodynamic Measurements
PYR dose (Sigma Aldrich, 40 mg/kg) was determined in a pilot study as the minimal dose able to reduce heart rate by 10% and increase parasympathetic activity, with minimal effects on systolic arterial pressure or animal activity ( Figure  II in the online-only Data Supplement). At week 6, PH status was confirmed by echocardiography, and animals were randomly assigned into PH (n=12) or PH-PYR (n=12). PYR was delivered in drinking water. At the end of the study, week 10, or earlier when animals developed signs of right heart failure, defined as >10% of body weight reduction, cyanosis, dyspnea, and lethargy, echocardiography and RV catheterization with pressure-volume analyses were performed as described before (see also Figure I in the online-only Data Supplement).
12,28
Heart Rate and Blood Pressure Variability Analysis
Cardiovascular autonomic function was assessed by power spectral analysis, applied to pulse interval and systolic arterial pressure series. Heart rate variability and blood pressure variability were evaluated at spectral domain using an autoregressive algorithm on stationary sequences of 200 beats. The low-frequency (0.25-0.75 Hz) and high-frequency (0.75-3.0 Hz) bands represented the sympathetic and parasympathetic modulation and were expressed in both absolute (heart rate variability: ms 2 , blood pressure variability: mm Hg2) and normalized units. The ratio between low-frequency and highfrequency components (low-frequency/high-frequency index) was considered a synthetic expression of the sympathovagal balance. 29, 30 The α-index was obtained from the square root of the ratio between the pulse interval and the systolic arterial ORIGINAL RESEARCH ARTICLE pressure variability within the low-frequency ranges, 31 and it was used to estimate spontaneous baroreflex sensitivity.
32,33
Histology of Heart and Lungs
After hemodynamic evaluation, rats were euthanized under isoflurane by exsanguination (by dissecting the abdominal aorta and inferior vena cava) with immediate removal of the vital organs. Heart and lungs were harvested and frozen. Cardiomyocyte cross-sectional area, cardiac fibrosis, and relative wall thickness of pulmonary arterioles were determined (see the online-only Data Supplement). Furthermore, RV capillary density, leukocyte infiltration, α-7nAchR, and m2AchR were measured by immunofluorescence (see the online-only Data Supplement).
Cholinergic System in Experimental PH
RV tissue of the rats was homogenized in radioimmunoprecipitation assay buffer containing phosphatase and protease inhibitors (Sigma-Aldrich). The protein concentration). Ten micrograms of protein was used to detect the expression of cholinergic receptors: α-7nAchR (1:1000; AB24644; Abcam) and m2AchR (1:1000; MA3-044; Thermo Scientific). The protein amount was normalized by GAPDH as loading control (1:50 000; G9295, Sigma-Aldrich). In addition, AchE activity (Methods in the online-only Data Supplement) was measured in plasma and RV homogenates.
Statistical Analysis
Statistical analyses were performed using Prism for Windows (GraphPad 6 Software). Data are presented as mean±SEM, P values of <0.05 were considered significant. Normality of data was checked, and either log-transformation or nonparametric testing was performed if data were not normally distributed. Unpaired t test was used to compare the general characteristics of patients with PAH and to compare AchE levels and cholinergic receptors expression between control and patients with PAH. The χ 2 test was used for categorical variables. The survival estimates were performed by Kaplan-Meier analysis, with post hoc comparison by log rank (Mantel-Cox) test between PH rats with/without PYR treatment. Two-way ANOVA for repeated measurements followed by Bonferroni post hoc test was used for heart rate recovery, echocardiography, and cell proliferation assay. One-way ANOVA with Bonferroni post hoc comparison between PH and PH-PYR was used for pressure-volume relationships, autopsy data, histology data, and protein analyses. The Kruskal-Wallis test followed by the Dunn multiple comparisons test was used for heart rate variability and blood pressure variability analyses. The heart rate and blood pressure variability data are presented in delta percentage before and after the treatment.
RESULTS
Reduced Parasympathetic Activity Was Associated With Reduced RV Function in Patients With PAH
To investigate whether parasympathetic activity is associated with RV function in patients with idiopathic/ hereditary PAH, we assessed heart rate recovery after the cardiopulmonary exercise test as a measure of parasympathetic activity and RVEF as a measure of RV function assessed by cardiac MRI. General patient characteristics and hemodynamics are presented in (Table) . The median RVEF was 41%. Patients with lower RVEF had increased N-terminal prohormone of brain natriuretic peptide levels, lower exercise capacity, higher resting heart rate, increased mean pulmonary artery pressure, and pulmonary vascular resistance (Table) . Patients with PAH had an impaired heart rate recovery at 30 and 60 seconds after maximal exercise, in comparison with control subjects ( Figure 1A ). It is important to note that, in patients with low RVEF, heart rate recovery (at both 60 and 120 seconds) was lower than in patients with higher RVEF ( Figure 1A ). These results indicate that reduced parasympathetic activity in patients with PAH is associated with a reduced RV function. 
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Local Changes in the Cholinergic System in Patients With PAH
Acetylcholine is the main parasympathetic nerve neurotransmitter and exerts its effect by binding to its nicotinic and muscarinic receptors. To investigate the local changes in the cholinergic system in the right ventricle, expression of the nicotinic receptors (α-7nAchR), muscarinic receptors (m2AchR), and AchE activity were assessed in RV tissue of patients with PAH and controls. We observed that α-7nAchR expression was upregulated in RV tissue from patients with PAH versus controls ( Figure 1B ), whereas no difference in m2AchR expression was found ( Figure 1C ). In addition, AchE activity was reduced in RV tissue of patients with PAH ( Figure 1D ).
To determine the local changes in the cholinergic system in the lung, we assessed the expression of α-7nAchR, m2AchR, and AchE activity in whole lung tissue and the pulmonary artery of patients with PAH and of controls. Both α-7nAchR and m2AchR expression were similar in lung homogenates of controls and patients with PAH ( Figure IIIA and IIIB in the online-only Data Supplement). However, because our immunofluorescence staining suggested higher α-7nAchR expression around the pulmonary arteries from patients with PAH ( Figure IIIC in the online-only Data Supplement), we further investigated the expression of α-7nAchR in pulmonary artery homogenates from patients with PAH versus controls, and again no significant difference was observed (Figure IIID in the online-only Data Supplement). In addition, m2AchR expression was also not significantly different in pulmonary artery homogenates from patients with PAH in comparison with controls ( Figure IIIE in the online-only Data Supplement). Moreover, reduced AchE activity was observed in MVECs and pulmonary arteries of patients with PAH ( Figure 1E and 1F) .
Based on these data, we hypothesize that the observed reduction in AchE activity may be an adaptive mechanism to the known autonomic imbalance observed in patients with PAH. However, because patients still experience an autonomic imbalance, this adaptation can be regarded as insufficient. The association of reduced parasympathetic activity with RV dysfunction ORIGINAL RESEARCH ARTICLE and local changes in cholinergic signaling in the RV and lungs in patients with PAH were the rationale to study the role of parasympathetic activity in more detail in an experimental model of PH.
Effects of PYR in Control Animals and in Human 3D Engineered Heart Tissue
In a pilot study (Material and Methods in the online-only Data Supplement, pilot dose finding), we found that PYR treatment at 40 mg/kg had no significant effects in RV end-systolic and end-diastolic pressures ( Figure  IV in the online-only Data Supplement) in healthy rats. In addition, no relevant differences on dP/dt maximum or dP/dt minimum were observed after PYR treatment ( Figure IV in the online-only Data Supplement). Furthermore, the effects of PYR were investigated in human 3D engineered heart tissue (EHT, Material and Methods in the online-only Data Supplement). Functional measurements in EHT were obtained at baseline and at 15 and 60 minutes after acetylcholine or PYR treatment. As observed in ( Figure IVE in the online-only Data Supplement) we confirmed that PYR and acetylcholine significantly reduced the heart rate on spontaneously beating EHTs. PYR also reduced the relaxation velocity after 60 minutes ( Figure IVF in the online-only Data Supplement). In addition, no significant effects of PYR treatment on maximum force and contraction velocity were observed ( Figure IVG and IVH in the online-only Data Supplement). These results confirmed that PYR had no relevant hemodynamic effect in controls.
PYR Improved Cardiovascular Autonomic Function in Experimental PH
To establish that PYR effectively stimulated parasympathetic activity in our PH-rat model, the cardiovascular autonomic function was assessed by heart rate and blood pressure variability analysis (Table I in the online-only Data Supplement). The typical power spectrum before and after the treatment from PH and PH-PYR groups can be appreciated at Figure 2A and 2B, the low-frequency component represents sympathetic activity and the high-frequency component represents parasympathetic activity. PYR significantly reduced the heart rate in comparison with vehicle ( Figure 2C ) and significantly increased the parasympathetic activity, measured by the high-frequency component of the heart rate variability obtained by spectral analysis ( Figure 2D ). Moreover, no significant changes in systemic arterial pressure ( Figure  VA in the online-only Data Supplement) and daily activity ( Figure VB in the online-only Data Supplement) were observed with the dose used. Through the blood pressure variability analysis, we observed that PYR reduced the sympathetic vascular component ( Figure 2E ) and improved the spontaneous baroreflex sensitivity ( Figure 2F ). In addition, PYR effectively reduced plasma AchE activity in our experimental-PH model ( Figure 2G ). No significant effects on AchE activity after PYR treatment were observed in RV homogenates ( Figure 2H ). These results confirmed that PYR treatment reduced plasma AchE activity and partially normalized cardiovascular autonomic function in our PH-rat model, without adverse side effects.
PYR Delayed Progression Toward Right Heart Failure
PH was confirmed before the start of PYR treatment in all PH rats (Table II in the online-only Data Supplement). Survival analysis demonstrated that PYR significantly delayed the time to manifest right heart failure in comparison with PH rats ( Figure 3A ). This finding was confirmed by serial echocardiographic analysis, where PYR treatment maintained RV systolic function, measured by tricuspid annular plane systolic excursion, stroke volume (Table III in the online-only Data Supplement), and cardiac output ( Figure 3B and 3C ). In addition, PYR reduced the pulmonary vascular resistance, RV wall thickness, and RV end-diastolic diameter ( Figure 3D through 3F).
PYR Improved RV Function
To determine the effect of PYR on load-independent parameters of RV function, RV pressure-volume analyses were performed at the end of the study (representative examples: Figure 4A 
PYR Reduced RV Remodeling and Inflammation
RV histological analyses were performed to analyze structural changes in the RV. RV cardiomyocyte crosssectional area ( Figure 5A , 5E, and 5I) and RV fibrosis were decreased with PYR ( Figure 5B , 5F, and 5J). Although RV myocardial capillary density was reduced in PH rats in comparison with controls, it was not significantly different after PYR ( Figure 5C , 5G, and 5K). RV myocardial leukocyte infiltration was observed in PH rats, which was not present in the left ventricle (Table IV in the online-only Data Supplement). PYR significantly reduced RV myocardial leukocyte infiltration ( Figure 5D , 5H, and 5L). Furthermore, we evaluated changes in the cholinergic receptors after PYR. Western blot and immunofluorescent analysis revealed that PYR reduced α-7nAchR and m2AchR expression in the RV (Figure 6A 
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Figure 2. Pyridostigmine improved cardiovascular autonomic function and reduced acetylcholinesterase activity in rats.
Relative changes at end of study (week 10) in comparison with baseline (week 6) on heart rate (HRV) and blood pressure variability (BPV). In summary, PYR restored the sympathovagal balance and thus (partially) normalized the cardiovascular autonomic function in experimental PH. A and B, Typical examples of a power spectrum (amplitude by heart rate frequency domains) that is the basis for the HRV analysis: the low-frequency component is a reflection of sympathetic activity and the high-frequency component reflects parasympathetic activity. The dashed lines represent the data at the start of treatment, and the continuous lines indicate the data at the end of study. As can be appreciated, the high-frequency-component increases after PYR (arrow in Figure 2B ). PYR reduced heart rate (C) and increased the parasympathetic activity (high-frequency-component) after the treatment (D). E and F, Data derived from the BPV analysis. E, The sympathetic vascular component is the low-frequency component from the BPV (in analogy of the low-frequency component of HRV), and the lowering effect of PYR in PH on this parameter is demonstrated. F, Spontaneous baroreflex sensitivity (α-index) is calculated by the square root of the ratio between the pulse interval and the systolic arterial pressure variability within the low-frequency components (sympathetic), the lowering effect of PYR on this parameter is demonstrated. Biochemical analysis confirmed that PYR intervention reduced plasma acetylcholinesterase (AchE) activity (G) and had no effect in RV AchE activity (H). Control: n=4, PH: n=4-6, PH-PYR: n=4-6; *P<0.05, **P<0.01, ***P<0.001 versus PH. PH indicates pulmonary hypertension; and PYR, pyridostigmine. 
PYR Reduced Pulmonary Vascular Remodeling
Pulmonary histology was subsequently performed to study structural changes that may explain the observed reduction in RV afterload. Histological analyses from pulmonary arterioles indicated a significant reduction in media and intima wall thickness after PYR treatment ( Figure 7A through 7E) . Moreover, PYR decreased the formation of occlusive vascular lesions ( Figure 7F ). To further investigate the effects of PYR on intima proliferation, we evaluated different PYR concentrations on proliferation of MVECs derived from controls and patients with PAH. Our in vitro study confirmed that PYR reduced the proliferation of MVECs ( Figure 7G , Figure  VI in the online-only Data Supplement). Taken together, these data suggest that PYR may have direct antiproliferative effects.
PYR Reduced Systemic and Pulmonary Inflammation
To assess the anti-inflammatory effects of PYR, we measured systemic and local inflammation in the lung.
In plasma, lower levels of interleukin-6 (730±24 versus 843±42, P=0.01; pg/mL) and monocyte chemoattractant protein-1 (1913±273 versus 3646±542, P=0.002; pg/mL) were observed in PH-PYR in comparison with the PH group. In addition, we observed a reduction in lung perivascular CD45+ cell infiltration in the PH-PYR group (293±44 versus 439±37, P=0.02; CD45+/mm 2 ). To assess whether the changes on pulmonary vasculature and inflammation could be explained by changes in the cholinergic signaling, the expression levels of α-7nAchR and m2AchR were measured by immunofluorescence in the pulmonary vasculature. However, no significant changes in α-7nAchR and m2AchR expression were observed ( Figure 7H and 7I, Figure VII in the online-only Data Supplement) after PYR. Downstream signaling of α-7nAchR was further analyzed. 34 Western blot analysis revealed no significant differences on phosphorylated-ERK, total-ERK, and NF-κB p65 expression in lung homogenates by PYR ( Figure VIII in the online-only Data Supplement). These findings suggest that PYR has direct antiproliferative and antiinflammatory effects that seem to be independent of α-7nAchR.
DISCUSSION
In this translational study, we demonstrated the clinical relevance of impaired parasympathetic activity in RV dysfunction and pulmonary vascular remodeling in PAH. 
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We were able to provide evidence of the following: 1. In patients with PAH, reduced parasympathetic activity was associated with reduced RV function. 2. In our PAH-rat model, increase in parasympathetic activity by PYR delayed the progression toward right heart failure. 3. PYR improved RV function, which was related to a reduction of inflammation, fibrosis, and normalization of cholinergic receptors in the right ventricle. 4. PYR also reduced RV afterload and pulmonary vascular remodeling, which was associated with direct antiproliferative and anti-inflammatory effects of PYR.
Sympathovagal Imbalance and RV Dysfunction in PAH
Previous studies have demonstrated impaired cardiovascular autonomic function and reduced parasympathetic nerve system activity in patients with PAH. 7, 35 Evaluation of parasympathetic activity in patients is challenging, but it can be indirectly assessed by heart rate variability spectral analysis and heart rate recovery after exercise and by evaluating the reflexes involved in heart rate changes, such as baroreflex sensitivity. 19 Lower high-frequency component of spectral analysis, 7 impaired heart rate recovery, 6, 35 and depressed baroreflex sensitivity 7, 8 have been described in patients with PAH. In addition, these parameters have been related to worse exercise capacity 7 and prognosis. 6 In the present study, we demonstrated that patients with reduced parasympathetic activity had a lower RVEF. In addition, we provide direct evidence that local parasympathetic activity of the RV is significantly changed. These findings suggest an important pathophysiological role of the parasympathetic nervous system. However, until now, no systematic evaluation in the context of PAH has been performed.
In (right) heart failure, an autonomic nervous system imbalance develops characterized by sympathetic overactivity and parasympathetic withdrawal. At the tissue level, the RV responds by reducing β-adrenergic receptor expression, and increasing nicotinic and muscarinic receptor expression. The preganglionic part of the parasympathetic system is mainly mediated by nicotinic receptors, and the postganglionic part is mainly mediated by muscarinic receptor, whereas the pre-and postganglionic neurons are connected in series. Our finding that nicotinic receptor expression was increased and AchE activity was reduced in the RV in PAH (Figure 1 ) is consistent with an adaptive, albeit inadequate, response to reduced parasympathetic signaling (Figure 8 ). This is further supported by the finding that treatment with PYR in PH rats resulted in a further reduction of AchE activity in plasma ( Figure 2G ). Representative examples of pressure-volume relationship for control, PH, and PH-pyridostigmine (PYR) groups. By preload reduction, multiple end-systolic pressure/volume points were obtained, from which the RV end-systolic pressure-volume relationship was derived (depicted by the solid rising line). Its slope is a load-independent measure for RV contractility (Ees). Similarly, the RV end-diastolic pressure-volume relationship and RV stiffness (Eed) were derived by preload reduction. RV afterload (Ea) was measured by RV end-systolic pressure at steady state divided by stroke volume (descending solid line; A through C). PYR significantly improved the RV contractility (D) and reduced RV stiffness (E). Moreover, PYR reduced RV afterload (F). Control: n=7, PH: n=8, PH-PYR: n=12. *P<0.05 versus PH. PH indicates pulmonary hypertension; and RV, right ventricle. ORIGINAL RESEARCH
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The involvement of the α-7nAchR in the cholinergic anti-inflammatory pathway is well described. Through this pathway, the vagal nerve exerts its anti-inflammatory effects by release of acetylcholine and the activation of this specific receptor. Vang et al 36 also found evidence of increased α-7nAchR expression in a cigarette smoke model. Furthermore, they observed that increased cardiac fibroblast proliferation and collagen content in RV of this mouse model was mediated via α-7nAchR. This is in line with our observations and suggests that the improvement in RV remodeling and RV inflammation by PYR could be mediated via the α-7nAchR.
It would be of interest to explore potential differences in RV α-7nAchR expression, local AchE activity, and RVEF efficiency in patients who have PAH with an adapted RV (RVEF>40%) versus patients with right heart failure (RVEF<40%). Unfortunately, the hemodynamic data from the RV tissue were not available. In addition, all RV tissue samples were obtained from patients who have PAH with end-stage right heart failure and a RVEF far below 40%, because they were all eligible for heart-lung transplantation.
In a recent article by DeMazumder et al, 22 a relationship between the muscarinic receptor and β-adrenergic receptor at the myocardial level was described. As an (initial) compensatory mechanism, the downstream effect of the β-adrenergic receptor was attenuated by the upregulation of the muscarinic receptors in their model of pacing-induced heart failure, which resulted in less calcium influx. Even though this protected the heart from arrhythmias; it also resulted in impaired contractility attributable to reduced protein kinase A-mediated phosphorylation. We previously demonstrated that protein kinase A phosphorylation is impaired in experimental and clinical PAH. 12, 37 Based on these studies, we propose that impaired parasympathetic activity observed in the present study may be a consequence of increased sympathetic nervous system and renin angiotensin-aldosterone system activities, which were previously described in patients with PAH. 5, 28, 38 Sympathetic and parasympathetic activities are linked in such a way that increased sympathetic activity results in reduced parasympathetic activity. Increased RV wall stress and reduced RV function 
ORIGINAL RESEARCH ARTICLE
are triggers for the increased neurohormonal activation observed in patients with PAH. Thus, reduced parasympathetic activity may be a direct consequence of the increased sympathetic activation in patients with PAH. We postulate that PYR not only enhances parasympathetic activity, but also reduces sympathetic activity, and therefore may restore the autonomic imbalance in PAH.
Sympathovagal Imbalance, Inflammation, and Pulmonary Vascular Remodeling in PAH
Increased levels of proinflammatory markers have been reported in patients with PAH. 39 In addition, these high levels of inflammatory mediators were associated with worse prognosis, 40, 41 suggesting an important role of inflammation in PAH pathogenesis. Previous studies in animal models of inflammation and left heart failure have described the beneficial effects of vagal nerve 42, 43 and cholinergic stimulation on the inflammatory response. 44, 45 However, until now, the anti-inflammatory effect of cholinergic stimulation in PAH was unknown. In the current study, we provided evidence that parasympathetic nervous system activation reduced systemic and local proinflammatory cytokine production, resulting in reduced RV and pulmonary vascular inflammation. The anti-inflammatory effect of a restoration of parasympathetic activity is mainly regulated via cholinergic stimulation mediated by nicotinic receptor activation and inhibition of the NF-κB pathway. 46, 47 However, direct effects of acetylcholine on chemokine production in tumor necrosis factor-treated macrophages 42 and Figure 6 . Pyridostigmine improved the cholinergic system in RV.
Representative RV immunofluorescence staining for α-7 nicotinic acetylcholine receptor (α-7nAchR; A) and muscarinic acetylcholine type 2-receptor (m2AchR; B) for control, PH, and PH-PYR groups. α-7nAchR and m2AchR (white), WGA (red), α-actinin (green), and nuclei (DAPI). Scale bar=20 µm. Western blot analyses revealed significant reduction of cholinergic α-7nAchR (C) and m2AchR (D) expression in the RV homogenates after PYR treatment. 43 In our study, nicotinic receptor expression in the pulmonary vasculature was unaltered. Moreover, downstream signaling of α-7nAchR in lung homogenates was unchanged after PYR treatment. Therefore, the anti-inflammatory and antiproliferative effects of parasympathetic stimulation observed in the pulmonary vasculature are unlikely mediated via α-7nAchR.
Clinical Relevance
In this study, we show that enhancing parasympathetic nervous system activity by PYR is beneficial in experimental PH. PYR is a long-approved drug, used in patients with myasthenia gravis, with a favorable pharmacological profile. Although no major side effects were observed in our experimental PH model, the safety and efficacy of PYR in patients with PAH should be investi- Representative images of pulmonary arterioles (elastica von Gieson, 40× magnification) for control, PH, and PH-PYR groups (A through C). PYR significantly improved the wall thickness of the pulmonary arterioles, as observed by media (D), intima thickness reduction (E), and formation of occlusive vascular lesions (F). In addition, PYR reduced human microvascular endothelial cell (MVEC) proliferation in vitro from control and pulmonary arterial hypertension (PAH) cells (G). Data presented as mean±SEM. *P<0.05, **P<0.01 comparison between 0 mmol/L dose versus 10 mmol/L. n=2 in each condition. Control: n=7, PH: n=8 and PH-PYR: n=12. **P<0.01, ***P<0.001, versus PAH. Immunofluorescence quantification for α-7 nicotinic acetylcholine receptor (α-7nAchR; H) and muscarinic acetylcholine type 2-receptor (m2AchR; I). There was no difference on receptor density after PYR treatment. Control: n=4, PH: n=4 and PH-PYR: n=4. PH indicates pulmonary hypertension; and PYR, pyridostigmine.
February 27, 2018
Circulation. 
Limitation
We did not include a PYR-control group in our main experimental study, based on evidence from prior studies that PYR does not have significant hemodynamic effects, 15, 48 and anticipated difficulties obtaining ethical approval for use of animals in studies of this nature. We acknowledge that PYR has not been studied specifically for the RV. However, our dose-finding study confirmed that PYR (40 mg/kg) did not have any relevant effect on RV function in controls. In addition, our novel data in human EHT also revealed no relevant effect of PYR on maximal force and force development.
In addition, we acknowledge that the exact mechanism by which parasympathetic activity is reduced in PAH remains unclear. The focus of this study was on the consequences of reduced parasympathetic activity and the therapeutic potential of (pharmacologically) enhancement.
In this translational study, we demonstrated that reduced RV function patients with PAH is associated with reduced parasympathetic activity. In addition, α-7nAchR is upregulated in the RV from patients with PAH. Furthermore, we also demonstrated reduced AchE activity in RV and MVECs from patients with PAH. These results are suggestive of an local adaptive response to reduced parasympathetic activity in patients with PAH. However, this compensatory mechanism may be insufficient, with persistence in autonomic dysfunction. Chronic parasympathetic nervous system stimulation in experimental PH can improve survival and RV function and reduce pulmonary vascular remodeling. The beneficial effects of PYR may be associated with reduced inflammation and normalized RV cholinergic receptors expression. Our findings revealed a novel potential therapeutic target in PAH, and provide evidence that encourage further clinical investigations to evaluate the safety and efficacy of PYR in patients with PAH.
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The online-only Data Supplement is available with this article at http://circ. ahajournals.org/lookup/suppl/doi:10.1161/CIRCULATIONAHA.117.027451/-/ DC1. A, Parasympathetic-related abnormalities in patients with PAH. B, Proposed mechanism for improved RV function, reduced RV afterload, and improved survival after pyridostigmine treatment. AchE indicates acetylcholinesterase; α-7nAchR, α-7 nicotinic acetylcholine receptor; m2AchR, muscarinic acetylcholine type 2-receptor; PAH, pulmonary arterial hypertension; and RV, right ventricular.
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